

**Adult CIRB - Late Phase Emphasis Meeting Agenda**

**January 19, 2023**

---

**I Continuing Review**

**A031701**, A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations (Version Date 01/13/21)

---

**II Continuing Review**

**A051902**, A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas (Version Date 07/02/21)

---

**III Continuing Review**

**A081105**, Randomized Study of Erlotinib Vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) (Version Date 01/20/21)

---

**IV Continuing Review**

**E3A06**, Randomized Phase III Trial of Lenalidomide versus Observation Alone In Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (Version Date 09/26/19)

---

**VI Continuing Review**

**NRG-BR007**, A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score  $\leq 18$  Breast Cancer (Version Date 03/05/21)

---